Journal Pre-proof



Longitudinal trajectories of plasma polyunsaturated fatty acids and associations with psychosis-spectrum outcomes in early adulthood

David Mongan, PhD, Benjamin I. Perry, PhD, Colm Healy, PhD, Subash Raj Susai, PhD, Stan Zammit, PhD, Mary Cannon, PhD, David R. Cotter, PhD.

PII: S0006-3223(24)01229-0

DOI: https://doi.org/10.1016/j.biopsych.2024.04.004

Reference: BPS 15468

To appear in: *Biological Psychiatry*

Received Date: 14 December 2023

Revised Date: 15 March 2024

Accepted Date: 7 April 2024

Please cite this article as: Mongan D., Perry B.I., Healy C., Susai S.R., Zammit S., Cannon M. & Cotter D.R., Longitudinal trajectories of plasma polyunsaturated fatty acids and associations with psychosis-spectrum outcomes in early adulthood, *Biological Psychiatry* (2024), doi: https://doi.org/10.1016/j.biopsych.2024.04.004.

Longitudinal trajectories of plasma polyunsaturated fatty acids and associations with psychosis-spectrum outcomes in early adulthood

Authors: David Mongan[1,2]*, PhD; Benjamin I. Perry[3,4]*, PhD; Colm Healy[2], PhD; Subash Raj Susai[2], PhD; Stan Zammit[5,6], PhD; Mary Cannon[2,7], PhD; David R. Cotter[2,7], PhD. *Joint first authors

1. Centre for Public Health, Queen's University Belfast, Northern Ireland
2. Department of Psychiatry, Royal College of Surgeons in Ireland University of Medicine and Health Sciences, Dublin, Ireland
3. Department of Psychiatry, University of Cambridge School of Clinical Medicine, Cambridge, United Kingdom
4. Cambridgeshire and Peterborough NHS Foundation Trust, Cambridge, United Kingdom
5. Centre for Academic Mental Health, Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, United Kingdom
6. Division of Psychological Medicine and Clinical Neurosciences, MRC Centre for Neuropsychiatric Genetics and Genomics, Cardiff University, Cardiff, United Kingdom
7. Future Neuro SFI Research Centre, Royal College of Surgeons in Ireland University of Medicine and Health Sciences, Dublin, Ireland

Corresponding author: Dr David Mongan, Centre for Public Health, Queen's University Belfast, Royal Victoria Hospital, Belfast, Northern Ireland. E-mail: davidmongan@rcsi.ie

Running title: PUFA trajectories and psychosis-spectrum outcomes

Word count (excluding abstract and references): 4000
Number of tables: 3
Number of figures: 2
Supplementary Information: Supplementary Methods; Tables S1-S6; Supplementary Figures S1-S5

Keywords: polyunsaturated fatty acid; omega-3; plasma; psychosis; negative symptoms; ALSPAC

ABSTRACT

Background: Evidence supports associations between polyunsaturated fatty acids (PUFAs) such as docosahexaenoic acid (DHA) and psychosis. However, PUFA trajectories in the general population have not been characterised and associations with psychosis-spectrum outcomes in early adulthood are unknown.

Methods: Plasma omega-6:omega-3 ratio and DHA %total fatty acids were measured by nuclear magnetic spectroscopy at 7,15,17 and 24years in the Avon Longitudinal Study of Parents and Children. Curvilinear growth mixture modelling evaluated BMI-adjusted trajectories of both measures. Outcomes were assessed at 24years. Psychotic experiences (PEs), At-Risk-Mental-State status, psychotic disorder and number of PEs were assessed using the Psychosis-Like Symptoms interview PLIKSi (*n*=3635, 2247 [61.8%]female). Negative symptoms score was measured using the Community Assessment of Psychic Experiences (*n*=3484, 2161 [62.0%]female). Associations were adjusted for sex, ethnicity, parental social class, cumulative smoking and alcohol use.

Results: Relative to stable average, the persistently high omega-6:omega-3 ratio trajectory was associated with increased odds of PEs and psychotic disorder, but attenuated on adjustment for covariates (PEs adjusted odds ratio[aOR] 1.63, 95% confidence interval[CI] 0.92-2.89; psychotic disorder aOR 1.69, 95%CI 0.71-4.07). This was also the case for persistently low DHA (PEs aOR 1.42, 95%CI 0.84-2.37; psychotic disorder aOR 1.14, 95%CI 0.49-2.67). Following adjustment, persistently high omega-6:omega-3 ratio was associated with increased number of PEs (β0.41, 95%CI 0.05-0.78) and negative symptoms score (β0.43, 95%CI 0.14-0.72), as was persistently low DHA (number of PEs:β 0.45, 95%CI 0.14-0.76; negative symptoms:β 0.35, 95%CI 0.12-0.58).

Conclusions: Optimisation of PUFA status during development warrants further investigation in relation to psychotic symptoms in early adulthood.

Abstract word count: 250 (max 250)

INTRODUCTION

There is growing interest in relationships between nutrition and mental health (1), including the potential role of polyunsaturated fatty acids (PUFAs). PUFAs, which must be obtained from the diet to maintain adequate levels, comprise two important subtypes. Omega-6 (n-6) fatty acids, including linoleic acid and arachidonic acid, are found in nuts, eggs and vegetable oils. Omega-3 (n-3) fatty acids, including alpha-linolenic acid, eicosapentaenoic acid and docosahexaenoic acid (DHA), are found in oily fish, some green vegetables or supplements.

Lipid mediators derived from n-6 and n-3 PUFAs have broadly opposing effects. For example, n-6 lipid mediators are generally pro-inflammatory, whereas n-3 lipid mediators predominantly reduce inflammation (2, 3). A n-6:n-3 ratio of 1–2:1 is considered optimal for normal physiological functioning (4). However, the average western diet typically has larger amounts of n-6 relative to n-3 PUFAs (5, 6). In the brain, the most abundant n-3 PUFA is DHA, which is postulated to have neuroprotective effects via modulation of neuronal membrane integrity, inflammation, oxidative stress and synaptogenesis (7).

Previous studies have provided evidence for associations between PUFAs and psychotic disorders. Meta-analyses have found lower erythrocyte membrane n-3 PUFA levels in people with schizophrenia (8) and lower DHA levels in individuals with first-episode psychosis (9) compared to controls. A Mendelian randomisation study reported associations between genetically-predicted levels of long-chain PUFAs and reduced schizophrenia risk, suggesting a causal relationship (10). A randomised controlled trial found n-3 supplementation reduced transitions to psychosis among individuals at clinical high-risk (11). These findings were not replicated in a subsequent trial (12), although a secondary analysis found increases in erythrocyte levels of n-3 and DHA predicted symptomatic and functional improvements (13).

In a general population study, higher plasma n-6:n-3 ratio and lower DHA levels were cross-sectionally associated with psychotic disorder in early adulthood (14). Higher DHA levels in late adolescence were longitudinally associated with reduced odds of incident psychotic disorder in early

adulthood, though not depressive disorder or generalised anxiety disorder (14). A further study found higher levels of n-6 PUFAs at age 7 were weakly associated with psychotic experiences at age 18, but effects attenuated on adjustment for confounders (15). These studies focused on PUFA measurements at a single timepoint. Repeated measures provide a more robust assessment of PUFA status compared to single measurements, which may overlook dynamic patterns of temporal variability. However, to date, longitudinal trajectories of PUFA levels have not been characterised in the general population, and associations between such trajectories and psychosis-spectrum outcomes are unknown.

We aimed to perform the first characterisation of longitudinal trajectories of plasma PUFA measures across multiple timepoints in a large general population cohort, and to evaluate associations between PUFA trajectories and psychosis-spectrum outcomes in early adulthood. Based on previous work (14), we focused *a priori* on two plasma measures: the ratio of n-6 to n-3 PUFAs; and DHA levels specifically. We hypothesised that trajectories characterised by higher n-6:n-3 ratio and lower DHA levels would be associated with increased risk of psychosis-spectrum outcomes.

METHODS AND MATERIALS

Participants and study design

The Avon Longitudinal Study of Parents and Children (ALSPAC) is a prospective birth cohort study (16-18). The study website details available data through a data dictionary and variable search tool (http://www.bristol.ac.uk/alspac/researchers/our-data/). Pregnant women in Avon, UK with expected delivery dates between 1st April 1991 to 31st December 1992 were invited. 14,541 pregnancies were enrolled with 13,988 children alive at 1 year. When the oldest children were approximately age 7, an attempt was made to bolster the initial sample with eligible cases who did not join originally. The sample size for data from age 7 is 15,454 pregnancies with 14,901 children alive at 1 year of age. Study data were collected and managed using REDCap (Research Electronic Data Capture) tools hosted at the University of Bristol (19, 20). REDCap is a secure, web-based software platform designed to support data capture for research studies.

Participants were invited to attend clinics at multiple timepoints where questionnaires, interviews and venepuncture were performed. For the current study, participants were included if they completed outcome assessments at age 24 and had PUFA data available at at least one timepoint.

Exposures

Plasma samples were collected at clinics when participants were aged approximately 7, 15, 17 and 24 years. Participants were requested to fast overnight or for at least 6 hours prior to the age 15, 17 and 24 clinics. Samples were collected according to a standardised protocol, centrifuged and stored at −80°C. The time ranges from sample collection to sending for analysis were: 12.6–14.8 years for the age 7 clinic; 4.3–6.4 years for the age 15 clinic; 2.4–5.1 years for the age 17 clinic; and 0.3–2.7 years for the age 24 clinic.

Fatty acid plasma levels were measured using high-throughput nuclear magnetic resonance spectroscopy (21). Based on previous work evaluating associations between plasma PUFAs and psychotic disorder (14), we focused *a priori* on two measures: the ratio of n-6 to n-3 PUFAs; and DHA expressed as percentage of total fatty acids.

Outcomes

We examined three binary and two continuous psychosis-spectrum outcomes at 24 years.

1. Psychotic experiences (PEs): At the age 24 clinic, participants completed the Psychosis-Like Symptoms Interview (PLIKSi) (22). The PLIKSi asks 12 core questions regarding PEs comprising hallucinations, delusions and experiences of thought interference. Participants who answered 'yes' or 'maybe' were cross-questioned to establish whether the experiences were psychotic. These were coded according to the Schedules for Clinical Assessment in Neuropsychiatry (23). Interviewers rated symptoms as 'not present', 'suspected' or 'definite' and whether attributable to sleep or fever. Participants met criteria for this outcome if they had at least one definite PE, not attributable to sleep or fever, that occurred in the previous six months.

2. At-Risk Mental State (ARMS): ARMS cases were identified by relating PLIKSi data to Comprehensive Assessment of At-Risk Mental State (CAARMS) and Structured Interview for Prodromal Symptoms criteria as previously described (24).

3. Psychotic disorder: In alignment with previous studies (24, 25), psychotic disorder was defined as having at least one definite PE not attributable to sleep or fever which recurred at least once per month over the previous six months, was associated with severe distress, marked impairment of the participant's social or occupational functioning, or led them to seek professional help. This outcome also included participants who met CAARMS criteria for psychotic disorder.

4. Number of suspected/definite PEs: This was defined as the total number of suspected or definite PEs reported by the participant during the PLISKi assessment (range 0–11).

5. Negative symptoms score: At the same clinic, participants completed ten questions from the Community Assessment of Psychic Experiences questionnaire (26) capturing interest, motivation, emotional reactivity, pleasure and sociability. Participants rated each item as occurring never, sometimes, often or always. These were recoded to never or sometimes (0) or often or always (1), then summed to give a total score from 0–10.

Confounders

Based on a systematic review of non-dietary factors associated with n-3 PUFA levels (27), the following available variables were considered as confounders: sex, ethnicity, body mass index (BMI) and cumulative measures of cigarette smoking and alcohol use. We also included parental social class of the participant's mother or father (whichever was highest) measured by questionnaire completed by mothers at 32 weeks gestation. For negative symptoms, models were additionally adjusted for depressive symptoms at age 24. Further details regarding measurement and rationale for included covariates are in Supplementary Methods.

Statistical analyses

At each timepoint, n-6:n-3 ratio and DHA levels were standardised to z-scores separately in males and females. Multiple imputation using Bayesian analysis (28, 29) was used to impute missing exposure and covariate data across ten imputed datasets. Several auxiliary variables were used as indicators of missingness to reduce the fraction of missing information, thus limiting 'missing not at random' bias (30) (see Supplementary Methods for further details). Tables S1 and S2 provide details on frequency of missing values for n-6:n-3 ratio and DHA respectively.

Curvilinear growth mixture modelling was used to derive longitudinal trajectories for n-6:n-3 ratio and DHA. Modelling was performed iteratively for 1-,2-,3- and 4-class solutions. The optimal number of classes was decided based on the average Bayesian information criterion (lower values indicate better fit), entropy (higher values indicate better fit) and smallest class proportion (≥1% in each class to permit further analysis with adequate sample sizes). Once achieving successful convergence, checks were performed to rule out local solutions by replicating estimation using the same seed values and comparing model parameter estimates for replication. A successfully converged model with no local solutions would have the best loglikelihood value repeated (31). Given recommendations to account for BMI as a potential confounder (27), and that BMI was assessed concurrently with plasma sampling at each timepoint, trajectories were adjusted for BMI.

Univariate multinomial logistic regression was used to characterise trajectory membership according to sociodemographic factors. Logistic regression was used to evaluate associations between trajectory membership and binary outcomes (definite PEs, ARMS and psychotic disorder), estimating odds ratios (ORs) and 95% confidence intervals (95% CI) compared to the commonest trajectory. Associations of trajectory membership with number of PEs and negative symptoms score were evaluated using negative binomial and linear regression respectively. For each outcome, results are presented for: unadjusted models; models adjusted for sociodemographic confounders (ethnicity, sex and parental social class); and models additionally adjusted for cumulative smoking and alcohol use.

Statistical analyses were performed in Stata v17 (StataCorp), MPlus v8 (Muthén&Muthén) and R v4.2.1 (R Project for Statistical Computing).

Ethical approval and consent

Ethical approval for ALSPAC was obtained from ALSPAC Ethics and Law Committee and local research ethics committees. Consent for biological samples was collected in accordance with the Human Tissue Act (2004). Informed consent for use of questionnaire and clinic data was obtained following recommendations of the ALSPAC Ethics and Law Committee at the time.

RESULTS

Of 4019 participants who attended the age 24 clinic, 3635 had PLIKSi data available and 3484 had negative symptoms data available. PUFA data were available for *n*=2268 at age 7, *n*=1896 at age 15 (*n*=1894 for n-6:n-3 ratio at age 15), *n*=1933 at age 17 and *n*=3163 at age 24 (Figure S1). Table 1 provides summary data for the analytical sample.

Longitudinal trajectories of n-6:n-3 ratio

For n-6:n-3 ratio trajectories, a 3-class solution was optimal (Table S3) comprising stable average (class 1: *n*=3282, 90.3%); slightly above average (class 2: *n*=61, 1.7%); and persistently high (class 3: *n*=292, 8.0%). Figure 1 plots n-6:n-3 ratio trajectories following adjustment for BMI. Trajectories without adjustment are shown in Figure S2. Individual trajectories are shown in Figure S3.

Compared to the stable average class, membership of the persistently high class was associated with female sex. For the slightly above average and persistently high classes, membership was associated with lower parental social class, higher BMI and higher cumulative smoking score (Table S4).

Longitudinal trajectories of DHA

For DHA trajectories, a 3-class solution was optimal (Table S2) comprising stable average (class 1: *n*=2739, 75.4%); persistently high (class 2: *n*=245, 6.7%); and persistently low (class 3: *n*=651,

17.9%). Figure 2 plots DHA trajectories following adjustment for BMI. Trajectories without adjustment are shown in Figure S4. Individual trajectories are shown in Figure S5.

Compared to the stable average class, membership of the persistently high class was associated with non-white ethnicity, higher parental social class and higher cumulative alcohol score. Membership of the persistently low class was associated with female sex, non-white ethnicity, lower parental social class, higher BMI and higher cumulative smoking score (Table S5).

Overlap between n-6:n-3 and DHA trajectory classes

As expected, there was substantial overlap between n-6:n-3 ratio and DHA trajectory classes. For example, 75.7% of those in the persistently high n-6:n-3 ratio class were in the persistently low DHA class (Table S6).

Psychosis-spectrum outcomes at age 24 years

Of 3635 participants with PLIKSi data available, 116 (3.2%) met criteria for definite PEs; 23 (0.6%) met criteria for ARMS; and 46 (1.3%) met criteria for psychotic disorder. 450 participants reported at least 1 suspected/definite PE, among whom the median was 1 (interquartile range 1). Of 3484 participants with negative symptoms data available, 1724 had a score of at least 1, among whom the median was 2 (interquartile range 4).

Associations between n-6:n-3 ratio trajectories and psychosis-spectrum outcomes

Table 2 details associations between n-6:n-3 ratio trajectories and psychosis-spectrum outcomes. There was evidence for association of the persistently high n-6:n-3 ratio trajectory with PEs and psychotic disorder, which attenuated on adjustment for covariates (PEs fully-adjusted OR 1.63, 95% CI 0.92–2.89; psychotic disorder fully-adjusted OR 1.69, 95% CI 0.71–4.07). There was little evidence for associations between n-6:n-3 trajectories and ARMS. There was evidence that the persistently high n-6:n-3 ratio trajectory was associated with number of PEs (fully-adjusted β 0.41, 95% CI 0.05–0.78) and negative symptoms (fully-adjusted β 0.43, 95% CI 0.14–0.72).

Associations between DHA trajectories and psychosis-spectrum outcomes

Table 3 details associations between DHA trajectories and psychosis-spectrum outcomes. There was evidence for association of the persistently low DHA trajectory with PEs and psychotic disorder, which attenuated on adjustment for covariates (PEs fully-adjusted OR 1.42, 95% CI 0.84–2.37; psychotic disorder fully-adjusted OR 1.14, 95% CI 0.49–2.67). There was little evidence for associations between DHA trajectories and ARMS. There was evidence that the persistently low DHA trajectory was associated with number of PEs (fully-adjusted β 0.45, 95% CI 0.14–0.76) and negative symptoms (fully-adjusted β 0.35, 95% CI 0.12–0.58).

DISCUSSION

To our knowledge, this is the first characterisation of longitudinal trajectories of plasma PUFA measures across childhood, adolescence and early adulthood in a large general population cohort. For both n-6:n-3 ratio and DHA, we found evidence for three longitudinal trajectories. Compared to stable average trajectories, persistently high n-6:n-3 ratio and persistently low DHA were associated with increased odds of PEs and psychotic disorder, with these associations explained by included covariates. Conversely, there was strong evidence for associations of high n-6:n-3 ratio and persistently low DHA with increased number of PEs and increased negative symptoms at age 24, which persisted on adjustment.

Higher levels of DHA at age 17 have previously been associated with reduced odds of incident psychotic disorder in early adulthood (14). A further study found higher levels of n-6 PUFAs at age 7 were weakly associated with PEs at age 18, but effects attenuated after adjustment for confounders (15). In this study, unadjusted analyses provided evidence of an association between persistently low DHA and increased odds of definite PEs and psychotic disorder, although these associations were explained by included confounders. One possibility is that longitudinal PUFA status is not associated with psychosis risk. However, this contrasts with the analyses of symptom-level outcomes. The relatively small number of individuals who met criteria for the binary outcomes examined (particularly ARMS or psychotic disorder) in this general population study may have limited

statistical power, increasing the risk of type II error. There was comparatively stronger evidence for associations between persistently high n-6:n-3 ratio and persistently low DHA in relation to number of PEs and negative symptoms score. The continuous nature of these symptom-level outcomes may have afforded greater power. It is also possible that the longitudinal effects of PUFAs are subtle, and thus detectable in relation to symptom-level dimensions rather than binary outcomes criteria.

The 'number of PEs' outcome included suspected and definite PEs and reflects the broadest examined outcome based on positive psychotic experiences. n-3 PUFA levels have been inversely associated with psychotic symptoms in individuals at clinical high-risk for psychosis (13) and n-3 supplementation has modest effects on general psychopathology and positive symptoms in people with schizophrenia (32). However, trials of PUFA supplementation for psychosis prevention in the clinical high-risk population have produced mixed results (11, 12, 33). In relation to negative symptoms, we found strong evidence for associations of persistently high n-6:n-3 ratio and persistently low DHA with negative symptoms at age 24. In the setting of psychotic disorders, negative symptoms are frequently associated with a high degree of disability and functional impairment, and are less responsive to standard treatments compared to positive symptoms (34). A previous meta-analysis found no improvement in negative symptoms associated with n-3 supplementation in schizophrenia (32). However, a secondary analysis of a randomised controlled trial in clinical high-risk individuals found increases in n-3 PUFA levels associated with improvement in negative symptoms (13).

Potential effects of PUFAs on subsequent risk of psychotic symptoms may not be adequately captured by the relatively short supplementation periods common in trials. Furthermore, existing trials of PUFAs for psychosis prevention focus on the clinical high-risk population (usually greater than 14 years of age). It is possible that early neurodevelopmental periods exist during which PUFA status is especially pertinent in relation to risk of psychotic symptoms, whether in childhood or adolescence (in keeping with the pruning hypothesis for schizophrenia (35)), or even prenatally. Evidence from animal studies suggests chronic n-3 deficiency is associated with disturbances in synaptic function (36), while offspring from maternal mice fed an n-3 deficient diet show increased synaptic elimination

in the developing hippocampus (37). The earliest PUFA measurement available for analysis in the current study occurred at age 7, such that earlier timepoints could not be captured in our analysis. Notably, there was no cross-over between PUFA trajectories across the examined exposure timeframe, suggesting trajectories were broadly fixed by age 7 years. Longitudinal patterns of prenatal and early childhood PUFA levels warrant exploration in further studies to determine whether an early critical period exists in relation to PUFA effects on psychosis risk.

The findings of this study are compatible with the idea that optimising PUFA status during development (whether through supplementation or dietary interventions) may be associated with reduction in psychotic symptoms in early adulthood. Clinically, minimally-invasive methods such as dried blood spot testing are available to measure and monitor n-3 PUFA levels without need for cold temperature storage (38). Targeting interventions towards children and young people with measured n-3 deficiencies may prove fruitful. However, the optimal developmental stage, duration and form of such interventions are not known. Furthermore, it is unclear whether targeting specific subpopulations (such as high-risk groups or people with established n-3 deficiencies) or the general population at large would yield optimal preventative benefits. Adequately-powered trials of PUFA supplementation and/or dietary interventions in early childhood (or prenatally) with long-term follow-up into early adulthood would be helpful. An additional challenge related to supplementation concerns the variable oxidation of fish oil products which could affect their efficacy (39). Omega-3 PUFAs, including DHA (40, 41), are capable of crossing the blood-brain barrier by passive diffusion or facilitated transport, but these processes are likely influenced by individual-level factors including age and health status (42). Further research in younger samples would be helpful to determine optimal age-appropriate dosing, bioavailability, administration and formulation strategies (for example, using PUFA-enriched meat rather than fish oil (43)). In the absence of sufficient trial evidence, existing guidance on PUFA intake should be followed (44, 45).

While Mendelian randomisation analyses support protective effects of long-chain PUFAs on schizophrenia risk (10), the underlying mechanisms are unclear. There is evidence for low-grade inflammation during and preceding psychosis (46). Modulation of inflammation and the innate

immune system is one potential mechanism by which PUFAs may influence psychosis outcomes (47, 48), although effects on oxidative stress and neurotransmission have also been suggested (49). Omega-3 PUFAs such as DHA promote neurite growth and synaptogenesis, and thus may limit the dysregulated synaptic pruning during adolescence that is hypothesised to underlie at least part of the pathophysiology of schizophrenia (35). Regarding brain morphology, deficits in right hippocampal growth during adolescence have been observed in young people who experienced psychotic experiences compared to controls (50). Higher hippocampal volume has been associated with higher omega-3 levels in cognitively healthy older adults (51), although whether a similar relationship underscores development of psychotic symptoms in young people is unconfirmed. Abnormalities in PUFA levels in those with or at risk of psychosis-spectrum outcomes could arise due to an underlying dysregulation of PUFA metabolism associated with liability to psychosis rather than from nutritional deficits alone. For example, genetic variation of fatty acid desaturase enzymes, elevated phospholipase A2 activity and abnormalities of fatty acid binding protein have been proposed in the setting of schizophrenia (49). This is potentially in keeping with the early dysregulation of wider lipid metabolism noted in some individuals at clinical high-risk of psychosis (52) and preceding psychotic experiences (53).

The present findings relate to a general population sample. While positive psychotic experiences have been extensively studied in this context (54), the extent to which the construct of negative symptoms applies to the general population is debated (55). Negative symptoms have been most prominently associated with chronic schizophrenia, but evidence from transdiagnostic studies suggests negative symptoms are prevalent to varying degrees in non-schizophrenia spectrum disorders and high-risk groups as well as in the general population (56-58). It is possible that the findings in the present study reflect associations between PUFAs and a non-specific latent factor of psychopathology more generally (akin to the '*p* factor' (59)). This will require further elucidation in diverse cohorts with repeated measures of PUFA levels.

Our findings suggest substantial proportions of the UK population evidence trajectories characterised by persistently high plasma n-6:n-3 ratio (approximately 8%) and persistently low DHA levels

(approximately 18%) compared to the population average. Average n-3 PUFA intake in the UK is already suboptimal compared to World Health Organisation recommendations (60, 61). Given several reported health benefits associated with n-3 PUFAs (62, 63), these findings have implications beyond psychosis. Notably, several sociodemographic factors were associated with trajectories characterised by persistently high n-6:n-3 ratio and low DHA levels. These patterns likely reflect effects of social determinants on diet and health (64, 65). The observed trajectories did not overlap following the first measurement at age 7, underscoring the importance of addressing social determinants in early life.

Limitations

Several limitations should be noted. Given the observational nature of this study, causality cannot be inferred and residual confounding is possible. PUFA levels may be a marker of dietary quality more broadly, and other associated dietary factors may confound observed associations. PUFA levels were measured in plasma rather than erythrocyte cell membranes. Plasma has the advantage of being less subject to degradation and greater stability in long-term storage (66). However, erythrocyte membrane levels have slower turnover and thus better reflect PUFA status in the preceding months, whereas plasma levels reflect a shorter timeframe of approximately 1-2 weeks (67, 68). While participants were requested to fast prior to the age 15, 17 and 24 clinics, this did not apply to the age 7 clinic. Our analyses were limited to those who attended and completed assessments for psychosis-spectrum outcomes at age 24. In common with most longitudinal cohorts, participants had varying amounts of missing data and attrition occurred in association with socioeconomic status. We used multiple imputation to avoid potential biases of complete-case analyses. The ALSPAC cohort is largely white and of higher socioeconomic status compared to the UK general population. This may limit the generalisability of our findings due to selection bias, particularly since dietary patterns can differ by ethnicity (69) and socioeconomic characteristics (70). Replication studies in more diverse and representative samples are thus warranted. Finally, the PLIKSi does not generate diagnoses according to DSM or ICD classifications, but it is likely that individuals who fulfilled the definition of psychotic disorder would also meet such criteria based on the frequency of psychotic symptoms and associated functional impairment.

Conclusions

We found evidence of three longitudinal trajectories for plasma n-6:n-3 ratio and DHA levels across childhood, adolescence and early adulthood in a large general population cohort. Trajectories characterised by persistently high n-6:n-3 ratio and persistently low DHA were associated with increased odds of PEs and psychotic disorder in early adulthood, with these associations explained by included covariates. Persistently high n-6:n-3 ratio and persistently low DHA trajectories were associated with increased number of PEs and negative symptoms in early adulthood. Further evidence, including replication in diverse cohorts with repeated PUFA measurements and trials with long-term follow-up into adulthood, would be helpful to further evaluate the longitudinal effects of PUFAs on psychosis-spectrum outcomes.

ACKNOWLEDGEMENTS

DM is supported by a Clinical Lectureship funded by Queen's University Belfast and the Belfast Health and Social Care Trust. BIP is supported by a Clinical Lectureship funded by the University of Cambridge and Cambridgeshire and Peterborough NHS Foundation Trust. CH is supported by the Health Research Board under grant number HRB ILP-PHR-2019-009. SRS is supported by the Health Research Board (HRB) under grant number HRB/HRA/PHR/2015-1293. MC is supported by a European Research Council Consolidator Award (iHEAR 724809). DC & CH are funded by a Wellcome Trust Innovations Award, number 220438Z/20/Z, and this publication has emanated from research supported in part by a research grant from Science Foundation Ireland (SFI) under Grant Number 21/RC/10294_P2 and co-funded under the European Regional Development Fund and by FutureNeuro industry partners. CH and MC are funded in part by the Health Research Board Investigator Lead Project (ILP-PHR-2019-009). SZ is supported by the NIHR Biomedical Research Centre at University Hospitals Bristol and Weston NHS Foundation Trust and the University of Bristol. The views expressed are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care.

The UK Medical Research Council and Wellcome Trust (Grant ref: 217065/Z/19/Z) and the University of Bristol provide core support for ALSPAC. This publication is the work of the authors and David Mongan will serve as guarantor for the contents of this paper. A comprehensive list of grants funding is available on the ALSPAC website (http://www.bristol.ac.uk/alspac/external/documents/grant-acknowledgements.pdf). Data collection for outcomes and exposures used in this research was funded by the Medical Research Council (MR/M006727/1 and MC_UU_12013/1).

We are extremely grateful to all the families who took part in ALSPAC, the midwives for their help in recruiting them, and the whole ALSPAC team, which includes interviewers, computer and laboratory technicians, clerical workers, research scientists, volunteers, managers, receptionists and nurses.

Data availability: Requests for access to ALSPAC data may be submitted to the ALSPAC executive committee as detailed on the study website: http://www.bristol.ac.uk/alspac/researchers/access/

DISCLOSURES

The authors report no biomedical financial interests or potential conflicts of interest.

TABLES

Table 1. Summary data for sample characteristics

	Analytical sample, *n*=3635	**Missing data, n (%)**
Sex, *n* (%)		0 (0%)
Female	2247 (61.8%)	
Male	1388 (38.2%)	
Ethnicity, *n* (%)		404 (11.1%)
White	3103 (96.0%)	
Non-White	128 (4.0%)	
BMI in kg/m^2, mean (SD)		
Age 7 years	16.2 (2.0)	542 (14.9%)
Age 15 years	21.3 (3.4)	896 (24.6%)
Age 17 years	22.6 (3.9)	832 (22.9%)
Age 24 years	24.8 (4.9)	34 (0.9%)
Parental social class at 32 weeks gestation based on occupation, *n* (%)		487 (13.4%)
I	627 (19.9%)	
II	1444 (45.9%)	
III	717 (22.8%)	
IV	258 (8.2%)	
V	92 (2.9%)	
VI	10 (0.3%)	
Cumulative smoking score		1542 (42.4%)
0	1786 (85.3%)	
1	173 (8.3%)	
2	98 (4.7%)	
3	36 (1.7%)	
Cumulative alcohol score		2574 (70.8%)
0	38 (3.6%)	
1	204 (19.2%)	
2	589 (55.5%)	
≥3	230 (21.7%)	
Plasma omega-6:omega-3 ratio, mean (SD)		
Age 7 years	10.5 (1.8)	1367 (37.6%)
Age 15 years	10.9 (2.2)	1741 (47.9%)
Age 17 years	10.2 (1.9)	1702 (46.8%)
Age 24 years	10.0 (1.6)	472 (13.0%)
Plasma DHA % total fatty acids, mean (SD)		
Age 7 years	1.1 (0.2)	1367 (37.6%)
Age 15 years	1.1 (0.3)	1739 (47.8%)
Age 17 years	1.1 (0.3)	1702 (46.8%)
Age 24 years	1.3 (0.3)	472 (13.0%)
Definite psychotic experiences at age 24 years		0 (0%)
No	3519 (96.8%)	
Yes	116 (3.2%)	

Psychotic disorder at age 24 years		0 (0%)
No	3589 (98.7%)	
Yes	46 (1.3%)	
At-Risk Mental State at age 24 years		0 (0%)
No	3612 (99.4%)	
Yes	23 (0.6%)	
Number of psychotic experiences at age 24 years		0 (0%)
0	3185 (87.6%)	
1	310 (8.5%)	
2	90 (2.5%)	
3	27 (0.7%)	
4	12 (0.3%)	
≥5	11 (0.3%)	
Negative symptoms score at age 24 years		151 (4.2%)
0	1760 (50.5%)	
1	575 (16.5%)	
2	312 (9.0%)	
3	225 (6.5%)	
4	176 (5.1%)	
5	140 (4.0%)	
≥6	296 (8.5%)	

BMI: body mass index; SD: standard deviation

Table 2. Associations between n-6:n-3 ratio trajectories and psychosis-spectrum outcomes in early adulthood

Outcome	Trajectory (reference: stable average)	Unadjusted			Adjusted for sex, ethnicity, parental social class			Further adjusted for smoking and alcohol use*		
Binary outcomes		**OR**	**95% CI**	***p***	**OR**	**95% CI**	***p***	**OR**	**95% CI**	***p***
Psychotic experiences	*Slightly above average*	1.77	0.56 – 4.25	0.341	2.51	0.35 – 18.22	0.362	1.94	0.27 – 14.20	0.511
	Persistently high	2.52	1.63 – 3.77	<0.001	2.15	1.25 – 3.68	0.006	1.63	0.92 – 2.89	0.092
At-Risk Mental State	*Slightly above average*	6.51	1.46 – 19.47	0.014	2.80	0.26 – 29.65	0.392	3.83	0.31 – 47.61	0.297
	Persistently high	2.67	0.96 – 6.25	0.079	2.52	0.79 – 8.05	0.118	2.19	0.61 – 7.91	0.231
Psychotic disorder	*Slightly above average*	3.06	0.70 – 8.71	0.130	2.49	0.22 – 28.02	0.459	2.05	0.18 – 23.07	0.561
	Persistently high	2.54	1.26 – 4.69	0.019	2.29	0.99 – 5.30	0.053	1.69	0.71 – 4.07	0.237
Continuous outcomes		**β**	**95% CI**	***p***	**β**	**95% CI**	***p***	**β**	**95% CI**	***p***
Number of suspected/ definite PEs	*Slightly above average*	0.34	-0.42 – 1.13	0.378	0.38	-0.65 – 1.40	0.473	0.24	-0.77 – 1.25	0.637
	Persistently high	0.71	0.38 – 1.06	<0.001	0.68	0.32 – 1.03	<0.001	0.41	0.05 – 0.78	0.026
Negative symptoms	*Slightly above average*	0.26	-0.33 – 0.86	0.384	0.17	-0.59 – 0.94	0.660	0.05	-0.66 – 0.76	0.887
	Persistently high	0.69	0.41 – 0.98	<0.001	0.69	0.39 – 0.98	<0.001	0.43	0.14 – 0.72	0.004

*Models evaluating associations with negative symptoms were additionally adjusted for depressive symptoms. OR: Odds ratio; CI: confidence interval.

Table 3. Associations between DHA trajectories and psychosis-spectrum outcomes in early adulthood

Outcome	Trajectory (reference: stable average)	Unadjusted			Adjusted for sex, ethnicity, parental social class			Further adjusted for smoking and alcohol use*		
Binary outcomes		**OR**	**95% CI**	***p***	**OR**	**95% CI**	***p***	**OR**	**95% CI**	***p***
Psychotic experiences	*Persistently high*	0.44	0.14 – 1.03	0.166	0.45	0.14 – 1.44	0.179	0.48	0.15 – 1.54	0.214
	Persistently low	2.20	1.56 – 3.07	<0.001	2.06	1.26 – 3.36	0.004	1.42	0.84 – 2.37	0.188
At-Risk Mental State	*Persistently high*	0.70	0.07 – 2.78	0.727	0.71	0.09 – 5.48	0.746	0.98	0.12 – 7.82	0.981
	Persistently low	1.58	0.68 – 3.37	0.339	1.20	0.38 – 3.76	0.760	0.90	0.26 – 3.18	0.873
Psychotic disorder	*Persistently high*	0.36	0.04 – 1.37	0.313	0.36	0.05 – 2.64	0.312	0.39	0.05 – 2.94	0.362
	Persistently low	1.92	1.10 – 3.23	0.045	1.79	0.81 – 3.93	0.149	1.14	0.49 – 2.67	0.756
Continuous outcomes		**β**	**95% CI**	***p***	**β**	**95% CI**	***p***	**β**	**95% CI**	***p***
Number of suspected/ definite PEs	*Persistently high*	-0.35	-0.83 – 0.12	0.151	-0.30	-0.77 – 0.17	0.213	-0.25	-0.72 – 0.22	0.300
	Persistently low	0.62	0.37 – 0.87	<0.001	0.70	0.40 – 1.01	<0.001	0.45	0.14 – 0.76	0.004
Negative symptoms	*Persistently high*	-0.12	-0.42 – 0.19	0.456	-0.08	-0.39 – 0.22	0.585	-0.08	-0.36 – 0.20	0.584
	Persistently low	0.63	0.43 – 0.83	<0.001	0.70	0.45 – 0.95	<0.001	0.35	0.12 – 0.58	0.003

*Models evaluating associations with negative symptoms were additionally adjusted for depressive symptoms. OR: Odds ratio; CI: confidence interval.

FIGURE LEGENDS

Figure 1. Trajectories of omega-6:omega-3 ratio, following adjustment for body mass index

Figure 2. Trajectories of docosahexaenoic acid (% total fatty acids), following adjustment for body mass index

REFERENCES

1. Adan RAH, van der Beek EM, Buitelaar JK, Cryan JF, Hebebrand J, Higgs S, et al. Nutritional psychiatry: Towards improving mental health by what you eat. Eur Neuropsychopharmacol. 2019;29(12):1321-32.
2. Schmitz G, Ecker J. The opposing effects of n−3 and n−6 fatty acids. Progress in Lipid Research. 2008;47(2):147-55.
3. Mariamenatu AH, Abdu EM. Overconsumption of Omega-6 Polyunsaturated Fatty Acids (PUFAs) versus Deficiency of Omega-3 PUFAs in Modern-Day Diets: The Disturbing Factor for Their "Balanced Antagonistic Metabolic Functions" in the Human Body. J Lipids. 2021;2021:8848161.
4. Park S, Lee JJ, Lee J, Lee JK, Byun J, Kim I, et al. Lowering n-6/n-3 Ratio as an Important Dietary Intervention to Prevent LPS-Inducible Dyslipidemia and Hepatic Abnormalities in ob/ob Mice. Int J Mol Sci. 2022;23(12).
5. Simopoulos AP. Evolutionary Aspects of Diet: The Omega-6/Omega-3 Ratio and the Brain. Molecular Neurobiology. 2011;44(2):203-15.
6. Lange KW. Omega-3 fatty acids and mental health. Global Health Journal. 2020;4(1):18-30.
7. Dyall SC. Long-chain omega-3 fatty acids and the brain: a review of the independent and shared effects of EPA, DPA and DHA. Front Aging Neurosci. 2015;7:52-.
8. Hoen WP, Lijmer JG, Duran M, Wanders RJ, van Beveren NJ, de Haan L. Red blood cell polyunsaturated fatty acids measured in red blood cells and schizophrenia: a meta-analysis. Psychiatry Res. 2013;207(1-2):1-12.
9. Fraguas D, Díaz-Caneja CM, Ayora M, Hernández-Álvarez F, Rodríguez-Quiroga A, Recio S, et al. Oxidative Stress and Inflammation in First-Episode Psychosis: A Systematic Review and Meta-analysis. Schizophrenia Bulletin. 2019;45(4):742-51.
10. Jones HJ, Borges MC, Carnegie R, Mongan D, Rogers PJ, Lewis SJ, et al. Associations between plasma fatty acid concentrations and schizophrenia: a two-sample Mendelian randomisation study. Lancet Psychiatry. 2021;8(12):1062-70.
11. Amminger GP, Schäfer MR, Papageorgiou K, Klier CM, Cotton SM, Harrigan SM, et al. Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial. Arch Gen Psychiatry. 2010;67(2):146-54.
12. McGorry PD, Nelson B, Markulev C, Yuen HP, Schäfer MR, Mossaheb N, et al. Effect of ω-3 Polyunsaturated Fatty Acids in Young People at Ultrahigh Risk for Psychotic Disorders: The NEURAPRO Randomized Clinical Trial. JAMA Psychiatry. 2017;74(1):19-27.
13. Amminger GP, Nelson B, Markulev C, Yuen HP, Schäfer MR, Berger M, et al. The NEURAPRO Biomarker Analysis: Long-Chain Omega-3 Fatty Acids Improve 6-Month and 12-Month Outcomes in Youths at Ultra-High Risk for Psychosis. Biol Psychiatry. 2020;87(3):243-52.
14. Mongan D, Healy C, Jones HJ, Zammit S, Cannon M, Cotter DR. Plasma polyunsaturated fatty acids and mental disorders in adolescence and early adulthood: cross-sectional and longitudinal associations in a general population cohort. Translational Psychiatry. 2021;11(1):321.
15. Thompson AD, Jones HJ, Heron J, Hibbeln J, Sullivan S, Zammit S. Omega-3 and Omega-6 fatty acids and risk of psychotic outcomes in the ALSPAC birth cohort. Schizophrenia research. 2020;224:108-15.
16. Boyd A, Golding J, Macleod J, Lawlor DA, Fraser A, Henderson J, et al. Cohort Profile: the 'children of the 90s'--the index offspring of the Avon Longitudinal Study of Parents and Children. Int J Epidemiol. 2013;42(1):111-27.
17. Fraser A, Macdonald-Wallis C, Tilling K, Boyd A, Golding J, Davey Smith G, et al. Cohort Profile: the Avon Longitudinal Study of Parents and Children: ALSPAC mothers cohort. Int J Epidemiol. 2013;42(1):97-110.
18. Northstone K, Lewcock M, Groom A, Boyd A, Macleod J, Timpson N, et al. The Avon Longitudinal Study of Parents and Children (ALSPAC): an update on the enrolled sample of index children in 2019 [version 1; peer review: 2 approved]. Wellcome Open Research. 2019;4(51).

19. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)—A metadata-driven methodology and workflow process for providing translational research informatics support. Journal of Biomedical Informatics. 2009;42(2):377-81.
20. Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O'Neal L, et al. The REDCap consortium: Building an international community of software platform partners. Journal of Biomedical Informatics. 2019;95:103208.
21. Soininen P, Kangas AJ, Wurtz P, Tukiainen T, Tynkkynen T, Laatikainen R, et al. High-throughput serum NMR metabonomics for cost-effective holistic studies on systemic metabolism. The Analyst. 2009;134(9):1781-5.
22. Horwood J, Salvi G, Thomas K, Duffy L, Gunnell D, Hollis C, et al. IQ and non-clinical psychotic symptoms in 12-year-olds: results from the ALSPAC birth cohort. The British journal of psychiatry : the journal of mental science. 2008;193(3):185-91.
23. Organisation WH. Schedules for Clinical Assessment in Neuropsychiatry. American Psychiatric Research. 1994.
24. Sullivan SA, Kounali D, Cannon M, David AS, Fletcher PC, Holmans P, et al. A Population-Based Cohort Study Examining the Incidence and Impact of Psychotic Experiences From Childhood to Adulthood, and Prediction of Psychotic Disorder. American Journal of Psychiatry. 2020;177(4):308-17.
25. Zammit S, Kounali D, Cannon M, David AS, Gunnell D, Heron J, et al. Psychotic Experiences and Psychotic Disorders at Age 18 in Relation to Psychotic Experiences at Age 12 in a Longitudinal Population-Based Cohort Study. American Journal of Psychiatry. 2013;170(7):742-50.
26. Stefanis NC, Hanssen M, Smirnis NK, Avramopoulos DA, Evdokimidis IK, Stefanis CN, et al. Evidence that three dimensions of psychosis have a distribution in the general population. Psychol Med. 2002;32(2):347-58.
27. de Groot RHM, Emmett R, Meyer BJ. Non-dietary factors associated with n-3 long-chain PUFA levels in humans - a systematic literature review. Br J Nutr. 2019;121(7):793-808.
28. Rubin D. Multiple Imputation for Nonresponse in Surveys: John Wiley & Sons; 1987.
29. Schafer J. Analysis of incomplete multivariate data. London: Chapman & Hall/CRC; 1997.
30. Dong Y, Peng CY. Principled missing data methods for researchers. Springerplus. 2013;2(1):222.
31. Jung T, Wickrama KAS. An Introduction to Latent Class Growth Analysis and Growth Mixture Modeling. Social and Personality Psychology Compass. 2008;2(1):302-17.
32. Goh KK, Chen CY-A, Chen C-H, Lu M-L. Effects of omega-3 polyunsaturated fatty acids supplements on psychopathology and metabolic parameters in schizophrenia: A meta-analysis of randomized controlled trials. Journal of Psychopharmacology. 2021;35(3):221-35.
33. Qurashi I, Chaudhry IB, Khoso AB, Omair Husain M, Hafeez D, Kiran T, et al. A randomised double-blind placebo-controlled trial of minocycline and/or omega-3 fatty acids added to treatment as usual for at risk Mental States: The NAYAB study. Brain Behav Immun. 2024;115:609-16.
34. Correll CU, Schooler NR. Negative Symptoms in Schizophrenia: A Review and Clinical Guide for Recognition, Assessment, and Treatment. Neuropsychiatr Dis Treat. 2020;16:519-34.
35. Howes OD, Onwordi EC. The synaptic hypothesis of schizophrenia version III: a master mechanism. Mol Psychiatry. 2023.
36. English JA, Harauma A, Föcking M, Wynne K, Scaife C, Cagney G, et al. Omega-3 fatty acid deficiency disrupts endocytosis, neuritogenesis, and mitochondrial protein pathways in the mouse hippocampus. Front Genet. 2013;4:208.
37. Madore C, Leyrolle Q, Morel L, Rossitto M, Greenhalgh AD, Delpech JC, et al. Essential omega-3 fatty acids tune microglial phagocytosis of synaptic elements in the mouse developing brain. Nature Communications. 2020;11(1):6133.
38. Liu G, Mühlhäusler BS, Gibson RA. A method for long term stabilisation of long chain polyunsaturated fatty acids in dried blood spots and its clinical application. Prostaglandins, Leukotrienes and Essential Fatty Acids. 2014;91(6):251-60.

39. Cameron-Smith D, Albert BB, Cutfield WS. Fishing for answers: is oxidation of fish oil supplements a problem? J Nutr Sci. 2015;4:e36.
40. Hachem M, Belkouch M, Lo Van A, Picq M, Bernoud-Hubac N, Lagarde M. Brain targeting with docosahexaenoic acid as a prospective therapy for neurodegenerative diseases and its passage across blood brain barrier. Biochimie. 2020;170:203-11.
41. Wen J, Satyanarayanan SK, Li A, Yan L, Zhao Z, Yuan Q, et al. Unraveling the impact of Omega-3 polyunsaturated fatty acids on blood-brain barrier (BBB) integrity and glymphatic function. Brain Behav Immun. 2024;115:335-55.
42. Pifferi F, Laurent B, Plourde M. Lipid Transport and Metabolism at the Blood-Brain Interface: Implications in Health and Disease. Front Physiol. 2021;12:645646.
43. Pérez-Palacios T, Ruiz-Carrascal J, Solomando JC, Antequera T. Strategies for Enrichment in ω-3 Fatty Acids Aiming for Healthier Meat Products. Food Reviews International. 2019;35(5):485-503.
44. Medicine I, Board F, Macronutrients A, Intakes S, Intakes S. Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids (Macronutrients)2005. 1-1331 p.
45. Association BD. Omega-3 2021 [Available from: https://www.bda.uk.com/resource/omega-3.html.
46. Mongan D, Ramesar M, Föcking M, Cannon M, Cotter D. Role of inflammation in the pathogenesis of schizophrenia: A review of the evidence, proposed mechanisms and implications for treatment. Early Intervention in Psychiatry. 2020;14(4):385-97.
47. Goldsmith DR, Rapaport MH. Inflammation and Negative Symptoms of Schizophrenia: Implications for Reward Processing and Motivational Deficits. Front Psychiatry. 2020;11:46.
48. Susai SR, Healy C, Mongan D, Heurich M, Byrne JF, Cannon M, et al. Evidence that complement and coagulation proteins are mediating the clinical response to omega-3 fatty acids: A mass spectrometry-based investigation in subjects at clinical high-risk for psychosis. Transl Psychiatry. 2022;12(1):454.
49. Hsu M-C, Huang Y-S, Ouyang W-C. Beneficial effects of omega-3 fatty acid supplementation in schizophrenia: possible mechanisms. Lipids in Health and Disease. 2020;19(1):159.
50. O'Neill A, Dooley N, Healy C, Carey E, Roddy D, Frodl T, et al. Longitudinal Gray Matter Development Associated With Psychotic Experiences in Young People. Biol Psychiatry Glob Open Sci. 2023;3(2):264-73.
51. Macaron T, Giudici KV, Bowman GL, Sinclair A, Stephan E, Vellas B, et al. Associations of Omega-3 fatty acids with brain morphology and volume in cognitively healthy older adults: A narrative review. Ageing Res Rev. 2021;67:101300.
52. Dickens AM, Sen P, Kempton MJ, Barrantes-Vidal N, Iyegbe C, Nordentoft M, et al. Dysregulated Lipid Metabolism Precedes Onset of Psychosis. Biological Psychiatry. 2021;89(3):288-97.
53. Madrid-Gambin F, Föcking M, Sabherwal S, Heurich M, English JA, O'Gorman A, et al. Integrated Lipidomics and Proteomics Point to Early Blood-Based Changes in Childhood Preceding Later Development of Psychotic Experiences: Evidence From the Avon Longitudinal Study of Parents and Children. Biol Psychiatry. 2019;86(1):25-34.
54. Staines L, Healy C, Murphy F, Byrne J, Murphy J, Kelleher I, et al. Incidence and Persistence of Psychotic Experiences in the General Population: Systematic Review and Meta-Analysis. Schizophr Bull. 2023;49(4):1007-21.
55. Emmerson LC, Ben-Zeev D, Granholm E, Tiffany M, Golshan S, Jeste DV. Prevalence and longitudinal stability of negative symptoms in healthy participants. International Journal of Geriatric Psychiatry. 2009;24(12):1438-44.
56. Strauss GP, Cohen AS. A Transdiagnostic Review of Negative Symptom Phenomenology and Etiology. Schizophr Bull. 2017;43(4):712-9.

57. Barragan M, Laurens KR, Navarro JB, Obiols JE. Psychotic-like experiences and depressive symptoms in a community sample of adolescents. Eur Psychiatry. 2011;26(6):396-401.
58. Havers L, Cardno A, Freeman D, Ronald A. The Latent Structure of Negative Symptoms in the General Population in Adolescence and Emerging Adulthood. Schizophr Bull Open. 2022;3(1):sgac009.
59. Caspi A, Houts RM, Belsky DW, Goldman-Mellor SJ, Harrington H, Israel S, et al. The p Factor: One General Psychopathology Factor in the Structure of Psychiatric Disorders? Clin Psychol Sci. 2014;2(2):119-37.
60. Pot GK, Prynne CJ, Roberts C, Olson A, Nicholson SK, Whitton C, et al. National Diet and Nutrition Survey: fat and fatty acid intake from the first year of the rolling programme and comparison with previous surveys. Br J Nutr. 2012;107(3):405-15.
61. Albar SA. Dietary Omega-6/Omega-3 Polyunsaturated Fatty Acid (PUFA) and Omega-3 Are Associated With General and Abdominal Obesity in Adults: UK National Diet and Nutritional Survey. Cureus. 2022;14(10):e30209.
62. Harris WS, Tintle NL, Imamura F, Qian F, Korat AVA, Marklund M, et al. Blood n-3 fatty acid levels and total and cause-specific mortality from 17 prospective studies. Nature Communications. 2021;12(1):2329.
63. Siriwardhana N, Kalupahana NS, Moustaid-Moussa N. Health benefits of n-3 polyunsaturated fatty acids: eicosapentaenoic acid and docosahexaenoic acid. Adv Food Nutr Res. 2012;65:211-22.
64. Patrick H, Nicklas TA. A Review of Family and Social Determinants of Children's Eating Patterns and Diet Quality. Journal of the American College of Nutrition. 2005;24(2):83-92.
65. Viner RM, Ozer EM, Denny S, Marmot M, Resnick M, Fatusi A, et al. Adolescence and the social determinants of health. The Lancet. 2012;379(9826):1641-52.
66. Metherel AH, Stark KD. The stability of blood fatty acids during storage and potential mechanisms of degradation: A review. Prostaglandins Leukot Essent Fatty Acids. 2016;104:33-43.
67. Sun Q, Ma J, Campos H, Hankinson SE, Hu FB. Comparison between plasma and erythrocyte fatty acid content as biomarkers of fatty acid intake in US women. Am J Clin Nutr. 2007;86(1):74-81.
68. Katan MB, Deslypere JP, van Birgelen AP, Penders M, Zegwaard M. Kinetics of the incorporation of dietary fatty acids into serum cholesteryl esters, erythrocyte membranes, and adipose tissue: an 18-month controlled study. Journal of Lipid Research. 1997;38(10):2012-22.
69. Bennett G, Bardon LA, Gibney ER. A Comparison of Dietary Patterns and Factors Influencing Food Choice among Ethnic Groups Living in One Locality: A Systematic Review. Nutrients. 2022;14(5).
70. Castetbon K, De Henauw S, Desbouys L, Méjean C. Socio-economic and cultural disparities in diet among adolescents and young adults: a systematic review. Public Health Nutrition. 2020;23(5):843-60.